Abstract
Introduction: Insulin remains the only recommended medical treatment for CFRD with little data on the clinical use of incretin mimetic agents such as the dipeptidyl peptidase-4 inhibitors ((DPP4-I) in CFRD despite recent paradigm shift in CF with modulator therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Paper Title
Journal
Date
